Azenosertib for uterine neoplasms

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 16 Apr 2024: Trial registered, NCT06369155
  2. 5 Mar 2025: Trial started, NCT06369155

The trials

NCT06369155: Azenosertib in Uterine Serous Carcinoma: Biomarker Study

State
Under way
Phase
Phase 2
People
25 planned
Started
5 Mar 2025
Primary completion
31 Jan 2027
Arms
Azenosertib
Results
None posted
  1. 16 Apr 2024: Trial registered
  2. 5 Mar 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.